Immunovia AB (publ) (IMMNOV.ST)

SEK 0.66

(1.23%)

Long Term Debt Summary of Immunovia AB (publ)

Immunovia AB (publ)'s latest annual long term debt in 2023 was 1.78 Million SEK , down -94.54% from previous year.
Immunovia AB (publ)'s latest quarterly long term debt in 2024 Q2 was - SEK , down 0.0% from previous quarter.
Immunovia AB (publ) reported annual long term debt of 32.7 Million SEK in 2022, up 20.42% from previous year.
Immunovia AB (publ) reported annual long term debt of 27.15 Million SEK in 2021, down -2.97% from previous year.
Immunovia AB (publ) reported quarterly long term debt of - SEK for 2024 Q2, down 0.0% from previous quarter.
Immunovia AB (publ) reported quarterly long term debt of 1.78 Million SEK for 2023 Q4, down -91.57% from previous quarter.

Annual Long Term Debt Chart of Immunovia AB (publ) (2023 - 2012)

Historical Annual Long Term Debt of Immunovia AB (publ) (2023 - 2012)

Year	Long Term Debt	Long Term Debt Growth
2023	1.78 Million SEK	-94.54%
2022	32.7 Million SEK	20.42%
2021	27.15 Million SEK	-2.97%
2020	27.98 Million SEK	-15.5%
2019	33.12 Million SEK	0.0%
2018	- SEK	0.0%
2017	- SEK	0.0%
2016	- SEK	0.0%
2015	- SEK	0.0%
2014	- SEK	0.0%
2013	- SEK	0.0%
2012	- SEK	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q1	- SEK	0.0%
2024 Q2	- SEK	0.0%
2023 Q4	1.78 Million SEK	-91.57%
2023 FY	1.78 Million SEK	-94.54%
2023 Q1	29.58 Million SEK	-9.51%
2023 Q2	22.9 Million SEK	-22.6%
2023 Q3	21.18 Million SEK	-7.49%
2022 FY	32.7 Million SEK	20.42%
2022 Q4	32.7 Million SEK	-6.6%
2022 Q3	35.01 Million SEK	-1.7%
2022 Q2	35.61 Million SEK	-1.24%
2022 Q1	36.06 Million SEK	32.81%
2021 Q2	30.19 Million SEK	-4.7%
2021 Q3	28.67 Million SEK	-5.04%
2021 Q4	27.15 Million SEK	-5.29%
2021 FY	27.15 Million SEK	-2.97%
2021 Q1	31.68 Million SEK	13.21%
2020 Q4	27.98 Million SEK	-9.42%
2020 FY	27.98 Million SEK	-15.5%
2020 Q3	30.9 Million SEK	1.21%
2020 Q2	30.53 Million SEK	-4.16%
2020 Q1	31.85 Million SEK	-3.83%
2019 Q2	29.24 Million SEK	-3.01%
2019 Q1	30.15 Million SEK	0.0%
2019 FY	33.12 Million SEK	0.0%
2019 Q4	33.12 Million SEK	-4.52%
2019 Q3	34.68 Million SEK	18.61%
2018 Q4	- SEK	0.0%
2018 Q2	- SEK	0.0%
2018 Q3	- SEK	0.0%
2018 FY	- SEK	0.0%
2018 Q1	- SEK	0.0%
2017 Q1	- SEK	0.0%
2017 Q2	- SEK	0.0%
2017 Q3	- SEK	0.0%
2017 Q4	- SEK	0.0%
2017 FY	- SEK	0.0%
2016 Q2	- SEK	0.0%
2016 Q1	- SEK	0.0%
2016 FY	- SEK	0.0%
2016 Q4	- SEK	0.0%
2015 Q3	- SEK	0.0%
2015 Q1	- SEK	0.0%
2015 Q4	- SEK	0.0%
2015 FY	- SEK	0.0%
2015 Q2	- SEK	0.0%
2014 Q1	- SEK	0.0%
2014 Q4	- SEK	0.0%
2014 FY	- SEK	0.0%
2014 Q3	- SEK	0.0%
2013 FY	- SEK	0.0%
2012 FY	- SEK	0.0%

Peer Long Term Debt Comparison of Immunovia AB (publ)

Name	Long Term Debt	Long Term Debt Difference
AroCell AB (publ)	- SEK	-Infinity%
Devyser Diagnostics AB (publ)	600 Thousand SEK	-197.833%
Prostatype Genomics AB (publ)	67 Thousand SEK	-2567.164%
SenzaGen AB	1.67 Million SEK	-6.814%
Spermosens AB	230 Thousand SEK	-676.957%